MedPath

The Causal Role of Ketone Bodies in Obesity-associated Disease Prevention - Combining Genetic Epidemiology with a Randomised Trial to Infer Causality

Not Applicable
Not yet recruiting
Conditions
Nutrition
Obesity and Overweight
Registration Number
NCT06668168
Lead Sponsor
University of Bath
Brief Summary

Excess weight increases the risk of several diseases including cardiovascular disease, type 2 diabetes, kidney disease and various cancers. There is a need for preventative strategies for obesity-associated disease, especially for people in the overweight and moderately obese ranges where pharmacological intervention may not be suitable.

Low-carbohydrate (ketogenic) diets are popular for weight control. Ketogenic diets increase circulating ketones, which can have favourable effects on cardiometabolic health markers. However, the ketogenic diet has a nutrient composition associated with harms (high-saturated fat/red meat, and low-fibre). The net effects of ketogenic diets on long-term health are unclear. Ketone supplements can increase circulating ketones and could provide benefits of ketosis without needing to adhere to a potentially harmful diet.

Establishing causality between complex exposures (e.g., diet) and long-term outcomes (e.g., disease), is challenging. The MRC \& NIHR Review of Nutrition and Human Health Research (2017) highlighted an "overreliance (as opposed to reasonable reliance) on observational studies" as a key barrier to progression in the field of nutrition and health. Randomised controlled trials (RCTs) facilitate causal inference, but for long-term outcomes are expensive, time-consuming, and often suffer from waning adherence. Mendelian randomization (MR) can estimate causal effects subject to key assumptions. A challenge to these assumptions includes complex behavioural exposures (e.g., diet), which could be intercorrelated with causal factors.

Our proposal will address these limitations with a novel combination of study designs to establish causal effects of ketosis (via diet and supplementation) on obesity-associated disease risk in humans.

We will combine a tightly controlled, short-term RCT, with MR to link short-term responses to long-term endpoints. We will examine the circulating (blood) and tissue-specific (adipose) transcriptomic and proteomic responses in the fasted and postprandial state in response to our dietary interventions and translate these to MR by identifying single-nucleotide polymorphisms from genome wide association studies. This approach overcomes limitations of RCTs and MR, as adherence to diets will be confirmed with controlled feeding, and intermediate molecular traits as exposure for MR are less likely to be intercorrelated with causal traits.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
69
Inclusion Criteria
  • Body mass index: 25-45 kg/m2
  • Fat mass index: : >6 kg/m2 for males, >9 kg/m2 for females
Exclusion Criteria
  • Glucose or lipid lowering medication
  • Diagnosis of cardiovascular disease, renal failure, liver disease or type 2 diabetes
  • Contraindications to a ketogenic diet (e.g., pancreatitis, liver failure, disorders of fat metabolism, primary carnitine deficiency, carnitine palmitoyltransferase deficiency, carnitine translocase deficiency, porphyrias, or pyruvate kinase deficiency)
  • Unable to understand English language

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Apolipoprotein B concentrationsFrom baseline to week 4

Plasma apolipoprotein B concentrations at week 4 adjusted for baseline values.

Fasting glucose concentrationsFrom baseline to week 4

Plasma fasting glucose concentrations at week 4 adjusting for baseline values

Urinary albumin concentrationsFrom baseline to week 4

Urinary albumin concentrations at week 4 adjusting for baseline values

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath